BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
HDFC Securities Institutional Equities
Shree Cement Ltd. - Shree Cement delivered strong margin despite both demand and cost headwinds. The company's Q3 FY22 standalone volume/Ebitda/adjusted profit after tax fell 9/24/21% YoY on account of weak demand, supply disruption from the Chhattisgarh plant, and elevated power costs.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Siemens India Ltd. - Siemens delivered Q1 FY22 revenue of Rs 32.4 billion (beat of 4.4%), impacted marginally by Covid-19 and disruption in supply chain caused by global semi-conductor shortage. Ebitda/adjusted profit after tax missed the estimate by 11.3/10.9% respectively, on account of higher commodity prices and lower forex gains.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Alkem Laboratories Ltd. - Alkem Labs' Q3 revenue/Ebitda beat our estimates by 2%/18%, led by good growth in India and international markets. It expects to outperform the Indian pharma market in the medium term.
Birla Corporation Ltd. - Poor demand and pricing mainly in the east along with rising fuel prices led to a consolidated decline of 6/2/39/64% YoY in volume/revenue/Ebitda/adjusted profit after tax for Birla Corp. Demand picked up in Q4, also aiding cost pass thorough capabilities.
Lupin Ltd. - Lupin's Q3 revenue/Ebitda missed our estimates by 1%/22%, primarily due to pressure on gross margin and higher research and development spends. Adjusted Ebitda margin dipped to 12.7%, the lowest in the past seven quarters.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
